Loading
A phase 2 trial of Sotorasib and Panitumumab in advanced solid tumours, run by Amgen, now recruiting.
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation is a phase 2 interventional study registered as NCT07172919 by Amgen, with 14 participants planned, started 2026-01-02 and due to reach its primary completion in 2028-07-01. Interventions recorded: Sotorasib and Panitumumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Amgen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/